7 completed, 5 unknown, 1 terminated. 5 Phase 2, 2 Phase 3, 2 Phase 4, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Unknown 3, Completed 2 |
| Phase 3 | 2 | Terminated 1, Unknown 1 |
| Phase 4 | 2 | Completed 2 |
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Pimozide: new trials by email Literature Review of Pimozide trials Research Report on Pimozide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Electrophysiological Effects of Potential QT Prolonging Drugs Clarithromycin, Pimozide, Placebo (Part 1) - Drug-induced QT Prolongation, Pharmacokinetics | Phase 1 | Completed | Food and Drug Administration (FDA) | 44 | 2023-03-21 | 2023-06-22 |
| Treatment for Post Acute COVID-19 Syndrome Pimozide 1 MG - Tinnitus, Subjective | Not applicable | Unknown | Applied Biology, Inc. | 50 | 2022-10-01 | 2022-08-22 |
| Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis Clozapine, haloperidol, pimozide, olanzapine, risperidone, amisulpride - Psychosis, Intellectual Disability | Phase 2 | Unknown | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 75 | 2020-11-26 | 2024-03-20 |
| A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) Pimozide 2mg/day (current) or 4 mg/day (study initiation), Placebo Oral Tablet - ALS, Amyotrophic Lateral Sclerosis | Phase 2 | Unknown | University of Calgary | 100 | 2017-10-27 | 2020-05-28 |
| Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate - Schizophrenia | Completed | Janssen Scientific Affairs, LLC | 296 | 2015-07-24 | 2019-01-23 | |
| A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS Pimozide 2 mg per day, Pimozide 4 mg per day, Placebo (Lactose tablet) - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Unknown | University of Calgary | 25 | 2015-04-01 | 2016-10-26 |
| Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients Olanzapine, Amisulpride, Risperidone - Schizophrenia, Schizophrenia and Disorders With Psychotic Features | Phase 4 | Completed | Technical University of Munich | 21 | 2015-02-01 | 2018-10-11 |
| Pharmacovigilance in Gerontopsychiatric Patients Phenobarbital, Phenytoin, Carbamazepine - Dementia, Depression | Phase 3 | Terminated | Hannover Medical School | 407 | 2015-01-01 | 2018-02-28 |
| Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis Discontinuation antipsychotic treatment, Antipsychotic treatment - Psychosis Nos/Other | Phase 3 | Unknown | Fundación Pública Andaluza Progreso y Salud | 104 | 2012-11-01 | 2014-12-05 |
| Antipsychotics and Risk of Hyperglycemic Emergencies Olanzapine, Risperidone, atypical antipsychotics (other) - Psychotic Disorders, Schizophrenia | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 725489 | 2012-04-01 | 2015-10-21 | |
| Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia Pimozide, Placebo - Schizophrenia, Psychotic Disorders | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 76 | 2004-10-01 | 2015-04-09 |
| Efficacy of Pimozide Augmentation for Clozapine Partial Response Pimozide, placebo - Schizophrenia | Phase 2 | Completed | Yale University | 28 | 2004-01-01 | 2016-03-04 |
| Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome pimozide - Tourette Syndrome | Phase 2 | Completed | National Center for Research Resources (NCRR) | 20 | 1993-02-01 | 2005-06-24 |
Schizophrenia (6) · Psychotic Disorders (4) · Amyotrophic Lateral Sclerosis (2) · Anxiety Disorders (1) · Bipolar Disorder (1) · Dementia (1) · Depression (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Drug-Related Side Effects and Adverse Reactions (1) · Intellectual Disability (1) · Mental Disorders (1) · Neurologic Manifestations (1) · Psychophysiologic Disorders (1) · Rare Diseases (1)
University of Calgary (2) · Applied Biology, Inc. (1) · Canadian Network for Observational Drug Effect Studies, CNODES (1) · Food and Drug Administration (FDA) (1) · Fundación Pública Andaluza Progreso y Salud (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Hannover Medical School (1) · Icahn School of Medicine at Mount Sinai (1) · Janssen Scientific Affairs, LLC (1) · National Center for Research Resources (NCRR) (1) · Technical University of Munich (1) · Yale University (1)
United States (4) · Canada (3) · Germany (2) · Spain (2)
Benedicto Crespo Facorro, Professor (1) · Handan Gunduz-Bruce, MD (1) · Helge Frieling, Prof., MD (1) · Jennifer Boston, MSN, APNP (1) · Joseph I. Friedman, MD (1) · Lawrence Korngut, M.D. (1) · Lawrence Korngut, MD, FRCPC (1) · Lorraine Lipscombe, MD, MSc (1) · Markus Dold, MD (1) · Miguel Ruiz Veguilla, MD, PhD (1) · Roger Kurlan (1) · Stefan Leucht, Professor (1)
PMID 21346734, PMID 24581419, PMID 35436231, PMID 38807685
R01MH067806 (1)